![]() |
市場調查報告書
商品編碼
1372469
生物製品外包市場規模 - 按產品(抗體、重組蛋白、疫苗)、服務(細胞和製程開發、分析測試)、來源(哺乳動物、微生物)、應用、最終用戶、全球預測,2023 - 2032 年Biologics Outsourcing Market Size - By Product (Antibodies, Recombinant Proteins, Vaccines), Service (Cell & Process Development, Analytical Testing), Source (Mammalian, Microorganism), Application, End-user, Global Forecast, 2023 - 2032 |
由於生物製藥公司與外包合作夥伴之間的研發合作日益受到重視,生物製品外包市場規模預計在 2023 年至 2032 年期間以 14.1% 的年複合成長率擴大。生物藥物開發和生產的複雜性不斷增加,加上合作關係,使得專業知識、技術和資源的共享成為可能,同時促進高效、及時地交付高品質產品。此類措施正在促進創新、加快產品開發時間並提高成本效益,以滿足生物製藥領域不斷變化的需求。
此外,隨著大量公司努力最佳化研發工作,該產業將在預測期內獲得顯著的發展動能。舉個例子,2023年10月,生物製藥開發商Tanvex BioPharma USA Inc.推出了Tanvex CDMO,為生物製藥行業提供全面的生物製劑合約開發和生產服務。
整個生物製品外包產業根據產品、服務、來源、應用、最終用戶和地區進行細分。
在產品方面,由於對先進疫苗開發和生產服務的需求不斷增加,預計2023年至2032年疫苗領域的市場規模將出現高需求。全球對預防性醫療保健的日益關注以及傳染病發病率的不斷增加,對高效、可擴展的疫苗生產解決方案的需求不斷增加。此外,生物技術的快速進步和對個人化醫療的日益重視將進一步推動該領域的成長。
預計到 2032 年,生物製品外包產業將受到血液相關產品開發應用領域的巨大吸引力。血液疾病的廣泛流行和對先進治療解決方案不斷成長的需求正在推動對專業生物製品外包服務的需求。此外,對個人化醫療的日益重視以及針對各種血液相關疾病的標靶生物療法的開發也將有助於擴大採用外包生物製劑服務。
從地區來看,在該地區製藥和生技產業不斷擴張的推動下,亞太地區生物製品外包產業預計將在 2023 年至 2032 年期間實現強勁成長。對先進生物療法的需求激增以及對個人化醫療的日益關注正在推動對專業外包服務的需求。此外,具有成本效益的製造能力和熟練的勞動力正在吸引全球生物製藥公司尋求高效和高品質的外包解決方案,進一步增強了該地區的行業前景。
Biologics Outsourcing Market size is poised to expand at 14.1% CAGR from 2023-2032 driven by the increasing focus on R&D collaborations between biopharmaceutical companies and outsourcing partners. The rising complexities of biological drug development and production along with collaborative partnerships are enabling the sharing of specialized expertise, technologies, and resources while facilitating the efficient and timely delivery of high-quality products. Such initiatives are fostering innovations, accelerating product development timelines, and enhancing cost-effectiveness for meeting the evolving demands of the biopharmaceutical field.
Moreover, with the large number of companies striving to optimize their R&D efforts, the industry will gain significant momentum in the forecast period. To cite an instance, in October 2023, biopharmaceutical developer Tanvex BioPharma USA Inc. launched Tanvex CDMO to provide comprehensive biologic contract development and production services to the biopharmaceutical sector.
The overall biologics outsourcing industry is segmented based on product, service, source, application, end-user, and region.
With respect to product, the market size from the vaccines segment is anticipated to witness high demand from 2023-2032 driven by the increasing demand for advanced vaccine development and production services. The rising focus on preventive healthcare worldwide and the increasing incidence of infectious diseases is escalating the demand for efficient and scalable vaccine manufacturing solutions. Moreover, the rapid advancements in biotechnology and the growing emphasis on personalized medicine will further boost the segment growth.
Biologics outsourcing industry is anticipated to foresee immense traction from the blood-related product development application segment through 2032. The widespread prevalence of blood disorders and the growing demand for advanced therapeutic solutions are propelling the need for specialized biologics outsourcing services. Moreover, the growing emphasis on personalized medicine and the development of targeted biologic therapies for various blood-related conditions will also contribute to the increasing adoption of outsourced biologics services.
Regionally, the Asia Pacific biologics outsourcing industry is estimated to record robust growth from 2023-2032 fueled by the expanding pharmaceutical and biotechnology sectors in the region. The surging demand for advanced biological therapies and the rising focus on personalized medicine is fueling the need for specialized outsourcing services. Additionally, the presence of cost-effective manufacturing capabilities and skilled workforce is attracting global biopharmaceutical several companies seeking efficient and high-quality outsourcing solutions, further augmenting the regional industry outlook.